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ABSTRACT  
 
Background: The associations of antiretroviral therapy (ART) with diabetes and metabolic 
syndrome are inconsistent and vary widely across primary epidemiological studies. A 
comprehensive and more precise estimate of these associations is fundamental to establishing 
plausible causal links between ART and these cardio-metabolic disorders.  
Methods: We identified epidemiological studies that compared mean fasting plasma glucose 
(FPG) concentrations and proportions of diabetes and metabolic syndrome between HIV-
infected patients naïve and exposed to ART. Mean difference (MD) in FPG concentrations 
and odds ratios (OR) of diabetes and metabolic syndrome were pooled using random-effects 
meta-analyses.  
Results: Data on 20,178 participants from 41 observational (30 cross-sectional, 1 case 
control and 10 cohort) studies were included in the meta-analyses. Mean FPG concentrations 
(Pooled MD: 4.66 mg/dl, 95% confidence interval [CI] 2.52 to 6.80, 24 studies) and the odds 
of diabetes (Pooled OR: 3.85, 95% CI 2.93 to 5.07, 10 studies) and metabolic syndrome 
(Pooled OR: 1.45, 95% CI 1.03 to 2.03, 18 studies) were significantly higher among ART-
exposed patients, compared to their naïve counterparts. ART was also associated with 
significant increases in FPG levels in studies with mean ART duration ≥ 18 months (Pooled 
MD: 4.97 mg/dl, 95% CI 3.10 to 6.84, 14 studies), but not in studies with mean ART duration 
< 18 months (Pooled MD: 4.40 mg/dl, 95% CI –0.59 to 9.38, 7 studies).  
Conclusion: ART may potentially be the single most consistent determinant of diabetes in 
people living with HIV worldwide. However, given the dominance of cross-sectional studies 
in the meta-analysis, the association between ART and diabetes may not be interpreted as 
cause and effect.  
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INTRODUCTION  
In contrast to the declining trends in AIDS-specific deaths, the era of highly active 
antiretroviral therapy has been marked by an increase in non-AIDS-defining illnesses, 
notably cardio-metabolic events, among people living with HIV [1]. Antiretroviral therapy 
(ART) potentially underlies the pathogeneses of cardio-metabolic disorders, such as diabetes 
mellitus and metabolic syndrome, in most people living with HIV [2,3]. While blood glucose 
levels tend to be slightly elevated in antiretroviral-naïve HIV-infected persons through 
mechanisms that remain unclear, evidence suggests that ART may exacerbate this effect by 
increasing insulin resistance and altering lipid metabolism [2,4]. Expectedly, these 
mechanisms may potentially explain a link between ART and the metabolic syndrome, given 
that the latter is a constellation of cardio-metabolic abnormalities that may involve elevated 
fasting plasma glucose concentrations [3]. In addition, metabolic syndrome ― widely 
acknowledged as a risk factor for type II diabetes in the general population ― has also been 
compared to the pre-diabetic state, the only distinction being the differences in diagnostic 
markers [5,6]. Diabetes and metabolic syndrome are among the chief drivers of the global 
epidemic of cardiovascular disease [7–10]. With approximately 36 million people currently 
living with HIV worldwide [11], and a projected 18 million incident cases by 2030 [12], 
ART-associated diabetes and metabolic syndrome may portend substantial public health 
burden, potentially worsening the already-existing global burden of cardiovascular disease. 
However, the associations of ART exposure with diabetes mellitus and metabolic syndrome 
have not been consistent and vary widely in magnitude across primary epidemiological 
studies, with certain studies reporting significant direct associations [13–16], and other 
studies reporting no significant effects [17–20]. Therefore, we aimed to obtain 
comprehensive and more precise estimates of the magnitudes of these associations. We also 
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sought to investigate study-level factors that may influence the associations of ART with 
diabetes and metabolic syndrome in people living with HIV worldwide. Assessing these 
associations may provide a comprehensive evidence-base for investigation plausible causal 
links between ART and these cardio-metabolic disorders.  
MATERIALS AND METHODS  
The study background, rationale and methods were specified in advance and documented in a 
study protocol registered in the PROSPERO database (CRD42014008855).  
Study selection  
CUN, AMS and OAU independently screened potentially eligible studies by their titles, 
abstracts and full texts, and any disparities were resolved following discussions with the other 
investigators. We selected studies that compared mean fasting plasma glucose concentrations 
and prevalence estimates of diabetes and metabolic syndrome between ART-exposed and 
ART-naïve HIV-infected adults. Other criteria for study selection are summarised in Table 1.  
Search strategy  
We searched PubMed, EMBASE and the World Health Organisation (WHO) International 
Clinical Trials Registry Platform for all relevant articles published to date. The search was 
conducted using medical subject heading (MeSH) terms and keywords: blood glucose*/, 
diabetes mellitus*/, metabolic syndrome X*/; highly active antiretroviral therapy*/, 
antiretroviral therapy*/, antiretroviral-naïve.mp/, HAART-naïve.mp/, HIV */. The electronic 
search was limited subsequently to studies of humans (see Appendices 1 and 2). We also 
scanned the bibliographies of relevant articles identified by the search.  
Data extraction  
CUN, AMS and OAU independently extracted data from each study using a piloted form and 
any discrepancies were also resolved by consensus with the other investigators. Data on the 
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following study-level characteristics were extracted: article citation, country of origin, 
country income group, geographical region, study design, sample size, mean age, proportion 
of females, proportion of current smokers and drinkers, number of ART-exposed and ART-
naïve patients, mean CD4 count, mean duration of ART, proportion of patients on protease 
inhibitors, mean concentrations of fasting plasma glucose in ART-exposed and ART-naïve 
patients, and the proportions of diabetes and metabolic syndrome in ART-exposed and ART-
naïve patients. Country income groups were defined according to World Bank development 
indicators [21]. Diabetes mellitus was defined as a fasting plasma glucose concentration ≥ 
126 mg/dl (7 mmol/l) or a two-hour post-prandial blood glucose level ≥ 200mg/dl (11.1 
mmol/l) [22]. Metabolic syndrome was defined as the presence of central obesity (waist 
circumference ≥ 94 cm for men and ≥ 80 cm for women) with any two of the following four 
criteria: serum triglyceride levels ≥ 150 mg/dl (or lipid lowering treatment); serum high 
density lipoprotein levels < 40 mg/dl in males and < 50 mg/dl in females (or specific 
treatment for this condition); blood pressure ≥ 130/85 mmHg (or antihypertensive treatment); 
fasting plasma glucose levels ≥ 100 mg/dl (or previously diagnosed type II diabetes mellitus) 
[23].  
Risk of bias assessment  
The methodological quality of each study was assessed using a domain-based checklist 
adapted from the Cochrane risk of bias tool for non-randomised studies [24] (Table 2). We 
investigated five potential sources of bias, including: the selection of participants (selection 
bias), assessment of the exposure (information bias), assessment of the outcomes 
(information bias), adjustment for potential confounders, and loss to follow-up of patients 
(attrition bias). Statistical analysis We pooled the weighted mean differences (MD) in fasting 
plasma glucose concentrations and the odds ratios (OR) of diabetes and metabolic syndrome 
in each study using the Dersimonian-Laird random-effects model, which is appropriate to 
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account for heterogeneity across the included studies [25]. The odds ratios of diabetes and 
metabolic syndrome were computed from their proportions in ART-exposed and ART-naïve 
patients. Heterogeneity across the included studies was measured using the I-squared statistic 
(I2) for which a value between 75% and 100% indicated considerable heterogeneity [26]. 
Chi-square tests for heterogeneity were also performed to determine the statistical 
significance of heterogeneity at 5% level. We investigated publication bias in each meta-
analysis using funnel plots and performed leave-one-study-out sensitivity analyses to 
ascertain the stability of the pooled effect estimates, which entailed omitting one study at a 
time while computing the meta-analyses. Random-effects subgroup and meta-regression 
analyses were performed on all study-level baseline characteristics to identify factors that 
may potentially modify the pooled associations, as well as possible sources of any observed 
heterogeneity across studies included in the meta-analyses [27]. The subgroups were 
categorized according to well-established predictors of cardio-metabolic disorders in people 
living with HIV (such as age ≥ 40 years, male sex, current smoking status) [28], and the 
potential for statistical interactions between obvious categories (such as study designs, 
country income groups, geographical regions and risk of bias categories) [27,29]. The effect 
estimates were reported with 95% confidence intervals (CI). Stata version 14 for Windows 
(Stata Corp, College Station, Texas) and Cochrane Review Manager (RevMan) software 
were used for all analyses and generation of figures.  
RESULTS  
Study selection and characteristics  
The study selection process is shown in Figure 1. From 602 records identified through 
electronic database searching, 19 records from cross-references, and 28,417 records from the 
WHO International Clinical Trials Registry Platform, we excluded 560 abstracts and 11 
duplicate records. Of 50 remaining full texts assessed for eligibility, nine articles were 
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withdrawn, leaving 41 studies that were deemed eligible for inclusion in the meta-analyses 
[13–20,30–62]. In total, there were 20,178 participants, with approximately twice as many 
ART-exposed as there were ART-naïve patients. The average age of the total study 
population was 42 years and women accounted for 40%. Most studies were conducted in 
low- and middle-income countries, including Brazil [19,40,41,59], Cameroon [39,42,51,57], 
Ethiopia [20,30,54], Ghana [56], India [33,49,52.53.60], Nigeria [32,38,55], South Africa 
[17,31], Sri Lanka [61], Thailand [14] and Zambia [46]. However, the studies conducted in 
high-income countries were generally larger in size, comprising more than half of the total 
study population. Table 3 summarizes other characteristics of the included studies.  
Risk of bias within included studies  
Selection bias was low in only ten studies (24%); information bias with respect to assessment 
of the exposure was low in all 41 studies, but unclear or high with respect to outcomes 
assessment in seven studies (83%); 34 studies (83%) adjusted for at least one important 
confounder; and loss to follow-up was less than 20% in eight out of 10 included cohort 
studies (Figure 2).  
Pooled association of ART with blood glucose concentration 
Figure 3 displays the meta-analysis of the association between ART and fasting plasma 
glucose concentrations. Mean fasting plasma glucose levels were compared between ART-
exposed and ART-naïve patients in 24 studies, 12 of which reported significantly higher 
mean concentrations in ART-exposed patients [14,19,30,38,41,46,49,56,58–61]. Overall, 
mean fasting plasma glucose levels remained significantly higher in ART-exposed patients, 
compared to their naïve counterparts (Pooled MD: 4.66 mg/dL; 95% CI 2.52 to 6.80; P < 
0.001; 5,069 participants). Heterogeneity across the included studies was considerable (I2 = 
81.2 %) and statistically significant (P < 0.001). Analysis of publication bias revealed a 
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symmetrical funnel plot (Supplementary Figure 1), and the pooled estimate did not change as 
to alter the interpretation of the association following serial exclusion of the included studies 
(Table 4).  
Table 5 presents the results of subgroup and meta-regression analyses. With the exception of 
sample size differences between studies, meta-regression analyses revealed no statistically 
significant differences between study-level subgroup estimates of the pooled association of 
ART with increased fasting plasma glucose concentration. The strength of the pooled 
association was significantly greater among studies with more than 200 participants (Pooled 
MD: 6.54 mg/dl; 95% CI 5.04 to 8.04; 12 studies), compared to studies with 200 participants 
or less (Pooled MD: 2.93 mg/dl; 95% CI 0.12 to 5.74; 12 studies) (P = 0.020 for interaction). 
Nonetheless, the qualitative interactions of the subgroup and meta-regression were also 
noteworthy. For instance, even though the difference between estimates of the pooled 
association were not statistically significant across the other study-level subgroups, it was 
observed that ART was significantly associated with increased blood glucose levels in studies 
where the mean duration of ART was at least 18 months (Pooled MD: 4.97 mg/dl; 95% CI 
3.10 to 6.84; 14 studies), whereas no significant association was observed in studies with 
mean ART duration of less than 18 months (Pooled MD: 4.40 mg/dl; 95% CI -0.59 to 9.38; 7 
studies). Unexpectedly, we found no significant associations between ART exposure and 
increased blood glucose levels in studies where the mean BMI was at least 25 kg/m 2 (Pooled 
MD: 1.87 mg/dl; 95% CI -5.75 to 9.49; 3 studies) and studies with more smokers than 
nonsmokers (Pooled MD: 4.13 mg/dl; 95% CI -0.04 to 8.29; 3 studies), whereas studies with 
mean BMI < 25 kg/m 2 (Pooled MD: 4.70 mg/dl; 95% CI 2.95 to 6.44; 16 studies) and fewer 
smokers than non-smokers (Pooled MD: 5.17 mg/dl; 95% CI 3.43 to 6.91; 11 studies) 
reported significant associations between ART exposure and increased blood glucose 
concentrations. However, in comparison to the numbers of participants in studies with mean 
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BMI < 25 kg/m 2 (n = 3,446) and studies with fewer smokers than non-smokers (n = 2,843), 
the numbers of participants in studies with mean BMI ≥ 25 kg/m 2 (n = 625) and studies with 
more smokers than non-smokers (n = 413) may have been too small to detect a statistically 
significant association between ART and blood glucose levels.  
Pooled association of ART with diabetes mellitus  
As shown in Figure 4, prevalence estimates of diabetes were compared between ART-
exposed and ART-naïve patients in ten studies, five of which revealed significantly higher 
odds of having diabetes in the ART-exposed group [13,14,47,54,56]. Among 7,946 
participants with reported diabetes status in the ART-exposed groups, 519 (6.5%) had 
diabetes, as opposed to 63 of 3,379 (1.9%) in the ART-naïve groups. Overall, the odds of 
having diabetes mellitus were approximately four times higher in ART-exposed patients, 
compared to their naïve counterparts (Pooled OR: 3.85; 95% CI 2.93 to 5.07; P < 0.001; 
11,328 participants). Studies included in the meta-analysis were not heterogeneous (I2 = 0%). 
Analysis of publication bias revealed the absence of small-study effects as indicated by the 
absence of funnel plot asymmetry (see Supplementary Figure 2), and sensitivity analysis 
showed no change in the pooled estimate that would alter the interpretation of the overall 
association of ART with increased odds of diabetes. (Table 4).  
There were no significant differences between subgroup estimates of the pooled association 
between ART exposure and diabetes. Nonetheless, in contrast to studies with less than 200 
participants (Pooled OR: 1.79; 95% CI 0.49 to 6.57; 3 studies), studies with more than 200 
participants were likely to report a significant association (Pooled OR: 4.06; 95% CI 3.06 to 
5.38; 7 studies) (Table 5).  
Pooled association of ART with metabolic syndrome  
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Prevalence estimates of metabolic syndrome were compared between ART-exposed and 
ART-naïve patients in 18 studies [14,16,18–20,31,33,34,36,37,39,41,43–45,50,51,55]. 
Among 5,548 ART-exposed patients with reported metabolic syndrome status, 1048 (18.9%) 
were diagnosed with metabolic syndrome, compared to 214 (14.2%) of 1,506 patients in the 
ART-naïve group. In addition, the odds of being diagnosed with metabolic syndrome were 
significantly higher among ART-exposed patients, compared to ART-naïve patients (Pooled 
OR: 1.45; 95% CI 1.03 to 2.03; P = 0.037; 7,052 participants) (Figure 5). Heterogeneity 
across the included studies was substantial (I2 = 69.4%) and statistically significant (P < 
0.001). Funnel plot was symmetrical (Supplementary Figure 3) and sensitivity analysis 
revealed no significant change in the pooled effect estimate following the sequential 
exclusion of studies from the meta-analysis (Table 4). Subgroup and meta-regression 
analyses also revealed no significant differences between subgroup estimates of the pooled 
association between ART exposure and metabolic syndrome. Nonetheless, the analyses 
revealed qualitative differences in the pooled association between studies of patients who 
were at least 40 years of age (Pooled OR 2.34; 95% CI 1.22 to 4.49; 7 studies) and those who 
were younger (Pooled OR: 1.14; 95% CI 0.67 to 1.95; 8 studies); studies with more women 
than men (Pooled OR: 1.66; 95% CI 1.28 to 2.14; 6 studies) and fewer women than men 
(Pooled OR: 1.49; 95% CI 0.81 to 2.72; 7 studies); and studies of patients from low/middle-
income countries (Pooled OR 1.61; 95% CI 1.26 to 2.04; 10 studies) and those from high-
income settings (Pooled OR: 1.27; 95% CI 0.63 to 2.53; 8 studies) (Table 5).  
DISCUSSION  
We present the first pooled analyses estimating the associations of ART with diabetes 
mellitus and the metabolic syndrome in people living with HIV worldwide. Overall, our 
findings revealed significant associations of ART with increased risks of diabetes and 
metabolic syndrome. HIV-infected patients on ART had approximately four and 1.5 greater 
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odds of developing diabetes mellitus and metabolic syndrome respectively, compared to 
patients naïve to ART. Importantly, there were no statistically significant variations in these 
pooled estimates across different socio-demographic and clinical characteristics, which 
suggests that ART may potentially be the single most consistent determinant of diabetes and 
metabolic syndrome in people living with HIV.  
Meta-regression analyses provided limited explanation for the observed heterogeneity across 
the included studies, but identified potential modifiers of the pooled associations. Schoenbach 
[63] and Kamangar [64] described two types of effect modification: quantitative modification 
occurs when the strength of the association between two variables differ significantly across 
subgroups of the modifier but the direction of the association remains the same, whereas 
qualitative modification is present when there is an association between two variables in one 
subgroup and not the other (or when the association in both subgroups occur in opposite 
directions). While our analyses revealed no quantitative modifiers, we found ART duration, 
age and sex to be qualitative moderators of the associations of ART with increased odds of 
blood glucose concentration and metabolic syndrome.  
Regarding ART duration, the observed association of ART exposure with increasing blood 
glucose levels in HIV-infected patients on ART for longer than 18 months but not in patients 
with shorter ART durations may suggest a plausible dose-response relationship between ART 
exposure and blood glucose levels. While our interpretation of this interaction somewhat 
contradicts previous studies reporting a lack of association between ART duration and fasting 
blood glucose concentrations [30,42], we cannot rule out the possibility that these two rather 
small-sized studies may not have been adequately powered to detect a significant association.  
The observed associations of ART with increased odds of metabolic syndrome in HIV-
infected patients above 40 years of age and in studies with more women than men, but not in 
younger patients or studies with fewer women than men, are broadly consistent with older 
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age and female sex as risk factors for cardio-metabolic disorders in HIV-infected persons 
exposed to ART [4,65]. In addition, the moderating influences of sex on the association 
between ART and metabolic syndrome is broadly consistent with higher rates of central 
obesity among women [66], especially given that central obesity remains a constant in the 
(IDF) definition of metabolic syndrome [23].  
Our findings may have important clinical and public health implications, especially for 
people living with HIV in low- and middle-income countries where care and treatment 
guidelines for HIV-infected patients do not entail baseline and routine blood glucose 
monitoring and other cardio-metabolic screening [67]. While our findings also suggest that 
downstream measures for preventing diabetes mellitus and other cardio-metabolic disorders 
in HIV-infected individuals may be more effectively targeted at patients considered to be 
high-risk, such as those aged over 40 years and those on antiretroviral therapy for more than 
18 months, future studies should also investigate the phenotypes on the HIV clinical 
spectrum that are most susceptible to the effects of ART on diabetes mellitus and metabolic 
syndrome, as well as the efficacies of targeted interventions in the defined phenotypes.  
This meta-analysis was limited by a number of factors. First, the observational nature of the 
included studies potentially precludes any causal inferences. Arguably, the ethical dilemma 
associated with the random allocation of HIV-infected patients to a placebo group diminishes 
the feasibility of a randomised controlled trial, emphasizing the need for observational data in 
estimating causality [68]. However, no temporal information is available for most of the 
studies included in the meta-analyses, given that the majority of these studies are cross-
sectional. It may very well be that HIV-infected patients with greater body mass indices are 
healthier than HIV-infected patients with lower body mass indices, and that this healthier 
state is associated with better compliance to ART or better access to antiretroviral drugs, so 
that there may be reverse causation, where diabetes and metabolic syndrome (untoward 
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effects of increased body mass index) lead to a greater exposure to ART. Indeed, the results 
of the subgroup and meta-regression analyses, which provide weighted estimates for the 
associations according to study design, show no significant association of ART with blood 
glucose or metabolic syndrome in the cohort studies and an extremely high association of 
ART with metabolic syndrome with a wide confidence interval in the single case control 
study. Although the cross-sectional studies show consistently positive associations of ART 
with blood glucose, diabetes and metabolic syndrome, but these associations may not be 
interpreted as cause and effect.  
Secondly, our findings are not generalizable to HIV-infected populations in the Eastern 
Mediterranean region, especially considering the high rates of diabetes in this region [7]. 
Given that geographical region may be used as proxy for genetic trait [69], the dearth of data 
from this region potentially limits any comprehensive assessment regarding what genetic 
traits may be most susceptible to the effects of ART on diabetes and metabolic syndrome. 
The inclusion of a larger proportion of HIV-infected patients from high-income countries, 
compared to low- and middle-income countries, also compromises generalization, given that 
the global prevalence of HIV and its untoward effects are driven by rates in low- and middle-
income countries [11].  
Thirdly, we acknowledge that the lack of data on glycated haemoglobin (HbA1c) levels is an 
important limitation of our study, especially with HbA1c now considered to be a better 
predictor of long-term diabetes risk than fasting plasma glucose concentrations in the general 
population [70].  
Furthermore, most of the included studies were assessed to have a high risk of selection bias. 
However, subgroup and meta-regression analyses revealed no significant differences in the 
pooled estimates between studies with high/unclear and low risks of selection bias (see Table 
5). In other words, the pooled estimates were not affected by selection bias.  
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Some of the unexplained heterogeneity across the included studies may have been driven by 
individual-level differences, such as differences in blood glucose concentrations prior to 
commencing antiretroviral therapy, varying histories of antidiabetic treatment, potential 
variations in the pharmacodynamic interactions between antiretroviral drugs and oral 
hypoglycaemic agents [71], and individual differences in lifestyle behaviours, such as alcohol 
abuse. However, individual-level differences were not examined in the meta-analyses.  
We could not examine the impact of certain lifestyle factors (such as smoking and alcohol 
use) and HIV-related characteristics (such as ART regimen, CD4 count, and HIV infection 
duration) on the associations of ART with diabetes mellitus and metabolic syndrome, given 
the insufficient number of studies required to perform these analyses [26].  
We did not examine the impact of antiretroviral therapy on gestational diabetes mellitus 
(GDM), given the dearth of evidence on this subject. Available data suggest that GDM 
prevalence estimates are statistically comparable between HIV-infected and HIV-non-
infected pregnant mothers [72]. Similarly, the American Diabetes Association 2016 
guidelines have not recommended different GDM screening protocols for HIV-infected and 
non-infected pregnant mothers [73].  
Lastly, with only two cohort studies in which the association between ART and diabetes 
mellitus were examined [17,47], it was impossible to distinguish ART-associated diabetes 
from diabetes developed prior to the commencement of ART [4].  
In spite of the above limitations, the timeliness of our study in filling an important gap by 
providing the most comprehensive and precise estimates quantifying the associations of ART 
with diabetes and metabolic syndrome in people living with HIV is noteworthy. Other 
important strengths of our study include: novel findings of moderators of the associations of 
ART on diabetes and metabolic syndrome; rigorous search strategies and methodological 
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assessments which were conducted by independent investigators; absence of small-study 
effects; and stability of the pooled estimates as confirmed by sensitivity analyses.  
In conclusion, the findings may preclude a cause and effect interpretation of the associations 
of ART with diabetes and metabolic syndrome, they (findings) add to a growing body of 
evidence, suggesting that the odds of developing diabetes or metabolic syndrome are high, 
above and beyond the role of traditional risk factors, among people living with HIV on 
antiretroviral treatment. These associations may also be modified by age, sex, and the 
duration of antiretroviral exposure, suggesting that this meta-analysis of over 20,000 HIV-
infected patients potentially supports the need for regular blood glucose monitoring and other 
cardio-metabolic screening in people living with HIV on ART. Future studies should 
investigate the phenotypes on the HIV clinical spectrum that are most susceptible to the 
effects of ART on cardio-metabolic disorders, as well as the efficacies of targeted treatments 
for the identified phenotypes.  
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Table 1: Inclusion and exclusion criteria 
 Inclusion  Exclusion 
Participants HIV-infected 
18 years of age and above 
HIV-negative 
Under 18 years of age 
Exposure  HAART HIV monotherapy 
Comparator HAART-naïveté  No HAART-naïve group  
Outcomes Fasting plasma glucose 
Diabetes mellitus  
Metabolic syndrome  
Other cardio-metabolic parameters/disorders 
Coronary heart diseases 
Study type Cross-sectional studies 
Case-control studies 
Cohort studies 
Randomised controlled trials 
Abstracts 
Expert reviews 
Conference proceedings 
 
HAART, highly active antiretroviral therapy  
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Table 2: Risk of bias assessment criteria for appraising the included studies 
Domain Assessment criteria 
 
 
 
 
 
 
Sampling of participants  
(Selection bias) 
Low risk:  
• Participants are sampled randomly 
• Similar recruitment strategies for ART-exposed and naïve 
participants 
• Sample size was justified 
 
High risk:  
• Participants are not selected randomly 
• ART-exposed and naïve participants recruited differently 
• Sample size was not justified 
 
Unclear risk: 
• Sampling strategy was not described 
• Sample size was not calculated 
 
 
 
 
 
Assessment of exposure  
(Information bias) 
Low risk:  
• Well-defined exposure criterion  
 
High risk:  
• Exposure criterion not well defined e.g. studies may 
define ART exposure based on treatment duration of at 
least one month, which misclassifies certain ART- 
 27 
exposed patients as ART-naïve  
 
Unclear risk:  
• Exposure criterion not stated 
 
 
 
 
 
Assessment of outcomes  
(Information bias) 
Low risk:  
• Blood glucose levels and diabetes risk are assessed 
similarly between ART-exposed and ART-naïve 
participants 
• Blood glucose levels and diabetes risk are assessed using 
validated methods 
 
High risk:  
• Blood glucose levels and diabetes risk are assessed 
differently between ART-exposed and ART-naïve 
participants 
• Blood glucose levels and diabetes risk are not measured 
using validated methods 
 
Unclear risk:  
• Methods for assessing blood glucose levels and diabetes 
risk are not clearly described 
 
 
Adjustment for confounding 
Low risk:  
• At least one major confounder is controlled  
 
High risk:  
• No attempt at adjusting for confounders 
 
Follow-up of participants –  
for cohort studies (Attrition bias) 
Low risk:  
• Loss to follow-up is less than 20%  
 
High risk:  
• Loss to follow-up is 20% or more 
Adapted after the Cochrane risk of bias tool for non-randomised studies 
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Table 3: Characteristics of the included studies 
First author Year Study design Country Income 
group 
Region N F  
(%) 
Age  
(years) 
BMI  
(kg/m2) 
CD4 
(cells/µL) 
Smokers 
(%) 
ART duration 
(months) 
PI (%) 
Abebe [30] 2014 Cross-sectional   Ethiopia Low/Middle Africa 252 72.2 35.3±10.2 – 364±199 – – 0 
Abrahams [17] 2015 Cohort South Africa Low/Middle Africa 103 100 33.5±2.5 27.9±3.5 372±53 – – 0 
Awotedu [31] 2010 Cross-sectional   South Africa Low/middle SSA 196 81 36.9±10.4 – – – – – 
Ayodele [32] 2013 Cross-sectional   Nigeria Low/Middle Africa 265 67.5 38.7±8.7 23.2±4.5 313±230 1.9 17.3±11.0 0 
Bajaj [33] 2013 Cross-sectional   India Low/middle S/E Asia 70 28.6 – – – –  49.5±27.0 – 
Bergersen [34] 2003 Cross-sectional   Norway High Europe 283 20.0 43.1±10.2 23.0±3.3 384±206 54.5 33.0±2.0  – 
Bergersen [15] 2006 Cross-sectional   Norway High Europe 263 19.4 43.1±20.1  – 313±230 1.9 – – 
Blumer [35] 2008 Cohort Netherlands High Europe 39  – 42.3±7.0 – 260±148  – 3.0 100 
Bonfati [18] 2007 Cross-sectional Italy High Europe 1243 28.2 43.2 23.6±3.3 – 60.2 – – 
Bonfati [36] 2012 Cohort Italy High Europe 188 24.5 39.5±11.1 – – – 18.5±8.8 46.5 
Calza [37] 2011 Cross-sectional Italy High Europe 755 – 37 – – – – – 
Denue [38] 2013 Cohort Nigeria Low/Middle Africa 229 51.1 43.5±9.3 24.4±4.1 246±166 5.7 24.0 0 
Dimodi [39] 2014 Cross-sectional   Cameroon Low/middle SSA 463 74.7 – – – 5.1 – 3.2 
Domingos [40] 2009 Cross-sectional   Brazil Low/Middle America 292 40.0 41.0±13.0 – –  15.4 40.4 60.2 
Eira [41] 2012 Cross-sectional   Brazil Low/Middle America 56  – 42.8±7.1 26.0±9.5 328±183 57.1 92.4±40.8  – 
Ekali [42] 2013 Cross-sectional   Cameroon Low/Middle Africa 143 72.0 39.5±9.8 24.5±3.4 253±167  – 43.5±21.3 0 
Fontas [13] 2004 Cohort   Multi-centre High Europe 7483 24.0 39±7.4 – 488±265 44.5 23.6±12.5 78.0 
Hansen [43] 2009 Cross-sectional   Denmark High Europe 466 18.6 45.5±10.2 25.1±8.6 519±233  – 60.0±51.5 73.0 
Howard [44] 2014 Cross-sectional   UK High Europe 100 – – – – – – 40.7 
Jantarapakde [14] 2014 Cross-sectional   Thailand Low/Middle Western Pacific 580 53.8 37.0±8.2 22.4±3.5 406±208 16.3 37.8±30.2 14.9 
Jerico [45] 2005 Cross-sectional   Spain High Europe 710 28 42±9.2 23.4±4.0 489±284 69.5 70.5±45.9 74.7 
Kiage [46] 2013 Cohort Zambia Low/Middle Africa 118 55.9 35.0±7.9 20.5±2.8 136±50 4.4 3.0 0 
Lin [47] 2011 Cohort Taiwan High Western Pacific 1344  – –  – –  –  49.5±27.0 –  
Magenta [48] 2011 Cohort Switzerland High Europe 74 12.0 40.0±10.0 24.9±4.8 258±112 65.0 20.4±8.3 100 
Malapati [49] 2014 Cohort India Low/Middle South-East Asia 229 –  46.3±9.3 24.4±4.1 246±167  – 12.0 0 
Maloberti [50] 2013 Cross-sectional Italy High Europe 108 – 43.6±7.7 – – – – – 
Mbunkah [51] 2014 Cross-sectional Cameroon Low/Middle Africa 173 71.1 38.7±11.4 23.7±3.8 332±168 2.9 – 28.9 
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Mital [52] 2013 Cross-sectional   India Low/Middle South-East Asia 200 –  –  22.6±2.9 –  17.5 –  0 
Mittal [53] 2013 Cross-sectional   India Low/Middle South-East Asia 40 32.5 36.1±7.2 20.3±3.8  – –  39.6±16.5 100 
Mohammed [54] 2015 Cross-sectional Ethiopia Low/Middle Africa 393 66.9 – – – – – – 
Muhammad [55] 2013 Cross-sectional   Nigeria Low/Middle Africa 200 53.0 32.5±7.6 – 319±206 9.0 45.0±19.5 1.0 
Ngala [56] 2013 Cross-sectional   Ghana Low/Middle Africa 305 61.0 38.5±8.7 24.0±4.7 – – 17.0±6.3 0 
Ngondi [57] 2007 Cohort Cameroon Low/Middle Africa 138 58.0 36.1±7.1 23.7±4.1 – – 12 0 
Samaras [16] 2007 Case-control Multi-centre High/Middle Multi-regional 788 16 43.5±9 25.0±3.5 – – – 50.4 
Shahmanesh [58] 2004 Cross-sectional   UK High Europe 55 18.2 40.0±10.4 23.6±2.9 424±225 41.8 39.8±8.8 37.5 
Silva [19] 2009 Cross-sectional Brazil Low/Middle America 319 38.9 39.5 24.4 532±422 26.7 – – 
Silva [59] 2010 Cross-sectional   Brazil Low/Middle America 314 44.6 37.7±7.9 – 531±313 26.7 52.8±42.0  – 
Sreekantamurthy [60] 2014 Cross-sectional   India Low/Middle South-East Asia 101 0 43.5±6.3 – – – 67.8±16.5 30.4 
Tesfaye [20] 2014 Cross-sectional Ethiopia Low/Middle Africa 374 68.0 32.6 – – – – – 
Weerakkody [61]  2013 Cross-sectional   Sri Lanka Low/Middle South-East Asia 268 42.2 39.5±9.6 21.4±3.9 390±243 20.1 33.0±23.0 7.3 
Wilson [62] 2009 Cross-sectional UK High Europe 458 16.8 39.5±8.9 24.5±4.0 545±83 41.5 77.4±33.0 39.0 
AIDS, Acquired Immune Deficiency Syndrome; ART, antiretroviral therapy; N, number of participants included in the analyses, F, females; PI, protease inhibitors; UK, United Kingdom; *Multiple, multi-centre. 
Values are expressed as mean ± standard deviation for age, CD4 count and duration of ART. 
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Table 4: Sensitivity analyses of the pooled associations of ART with blood glucose, 
diabetes and metabolic syndrome. 
 
 
 
 
 
Outcomes 
 
 
 
Pooled estimate prior to  
exclusion of studies 
 
 
 
Range of pooled 
estimate after 
sensitivity analyses 
Pooled estimate after 
exclusion of study 
significantly changed 
interpretation of the 
overall association 
Pooled ES (95% CI) Pooled ES (95% CI) 
Fasting plasma glucose 4.66 (2.52 to 6.80) 4.48 to 5.08 ― 
Diabetes Mellitus 3.85 (2.93 to 5.07) 3.81 to 3.85 ― 
Metabolic Syndrome 1.45 (1.03 to 2.03) 1.42 to 1.59 ― 
CI, confidence interval; ES, effect size. No study had undue influence on the pooled estimates.
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Table 5: Subgroup estimates and meta-regression analyses of the pooled associations of ART with blood glucose, diabetes and metabolic syndrome. 
 Blood glucose (mg/dL)  Diabetes mellitus  
 
Metabolic syndrome 
 
Study-level characteristics 
 
N 
Pooled MD  
(95% CI) 
 
P-value 
  
N 
Pooled OR  
(95% CI) 
 
P-value 
  
N 
Pooled OR  
(95% CI) 
 
P-value 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
Western Pacific 
Multi-regional 
 
9 
5 
5 
4 
1 
– 
 
3.29 (-0.48 to 7.06) 
3.34 (1.15 to 5.53) 
5.89 (2.67 to 9.10) 
7.92 (5.40 to 10.44) 
6.90 (4.89 to 8.91) 
– 
 
 
 
 
 
0.313 
  
4 
1 
– 
1 
2 
1 
 
3.35 (1.29 to 8.67) 
2.03 (0.43 to 9.52) 
– 
8.96 (0.53 to 152.53) 
3.69 (2.32 to 5.88) 
4.20 (2.84 to 6.23) 
 
 
 
 
 
 
0.727 
  
5 
8 
1 
2 
1 
1 
 
1.62 (1.19 to 2.20) 
1.27 (0.63 to 2.53) 
0.85 (0.25 to 2.91) 
1.20 (0.60 to 2.40) 
1.75 (1.10 to 2.80) 
12.78 (1.75 to 93.14) 
 
 
 
 
 
 
0.818 
Income group 
High income 
Low/middle 
 
5 
19 
 
3.34 (1.15 to 5.53) 
5.07 (2.45 to 7.69) 
 
 
0.469 
  
3 
7 
 
4.03 (2.82 to 5.76) 
3.62 (2.33 to 5.61) 
 
 
0.434 
  
8 
10 
 
1.27 (0.63 to 2.53) 
1.61 (1.26 to 2.04) 
 
 
0.841 
Age group 
< 40 years 
≥ 40 years 
 
13 
9 
 
4.46 (1.43 to 7.49) 
5.44 (3.39 to 7.49) 
 
 
0.502 
  
8 
2 
 
3.76 (2.82 to 5.02) 
4.89 (1.98 to 12.09) 
 
 
0.643 
  
8 
7 
 
1.14 (0.67 to 1.95) 
2.34 (1.22 to 4.49) 
 
 
0.845 
Females 
≤ 50% 
> 50% 
 
10 
10 
  
5.69 (3.86 to 7.51) 
3.80 (0.04 to 7.56) 
 
 
0.341 
  
 
– 
 
 
– 
 
 
– 
  
7 
6 
 
1.49 (0.81 to 2.72) 
1.66 (1.28 to 2.14) 
 
 
0.701 
Body mass index 
< 25 kg/m2 
≥ 25 kg/m2 
 
16 
3 
 
4.70 (2.95 to 6.44) 
1.87 (-5.75 to 9.49) 
 
 
0.146 
  
 
– 
 
 
– 
 
 
– 
  
6 
4 
 
1.63 (1.09 to 2.44) 
2.34 (1.32 to 4.16) 
 
 
0.795 
Smokers 
≤ 50% 
> 50% 
 
11 
3 
 
5.17 (3.43 to 6.91) 
4.13 (-0.04 to 8.29) 
 
 
0.692 
  
 
– 
 
 
– 
 
 
– 
  
 
– 
 
 
– 
 
 
– 
HIV duration 
< 60 months 
≥ 60 months 
 
6 
6 
 
5.63 (3.10 to 8.15) 
4.83 (2.00 to 7.67) 
 
 
0.714 
  
 
– 
 
 
– 
 
 
– 
  
 
– 
 
 
– 
 
 
– 
PI-based ART regimen 
≤ 50%  
> 50% 
 
15 
5 
 
4.45 (1.62 to 7.27) 
3.79 (0.66 to 6.93) 
 
 
0.839 
  
 
– 
 
 
– 
 
 
– 
  
 
– 
 
 
– 
 
 
– 
ART duration 
< 18 months 
≥ 18 months 
 
7 
14 
 
4.40 (-0.59 to 9.38) 
4.97 (3.10 to 6.84) 
 
 
0.615 
  
 
– 
 
 
– 
 
 
– 
  
 
– 
 
 
– 
 
 
– 
Study design 
Case-control 
Cohort 
Cross-sectional 
 
– 
7  
17 
 
– 
4.11 (-0.75 to 8.96) 
4.93 (3.23 to 6.62) 
 
 
 
0.479 
  
– 
2 
8 
 
– 
4.57 (1.83 to 11.39) 
3.79 (2.84 to 5.05) 
 
 
 
0.637 
  
1 
1 
16 
 
12.78 (1.75 to 93.14) 
0.43 (0.14 to 1.08) 
1.45 (1.04 to 2.02) 
 
 
 
0.610 
Selection bias 
High/unclear 
Low 
 
19 
5 
 
4.61 (2.08 to 7.14) 
3.70 (1.04 to 6.36) 
 
 
0.832 
  
7 
3 
 
3.54 (2.37 to 5.29) 
4.15 (2.85 to 6.04) 
 
 
0.695 
  
15 
3 
 
1.41 (0.97 to 2.06) 
1.94 (0.54 to 6.97) 
 
 
0.769 
–, insufficient number of observations to perform analysis; ART, antiretroviral therapy; CD4, cluster of differentiation 4; MD, mean difference; MD, mean difference; N, number of studies; OR, odds ratio; PI, 
protease inhibitor 
 
